Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Q901
i
Other names:
Q901
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Lead Discovery Center, Qurient
Drug class:
CDK7 inhibitor
Related drugs:
‹
YPN-005 (7)
SY‑079 (4)
SY-5609 (3)
CT7001 (3)
TG02 (2)
BTX-A51 (1)
KRLS-017 (1)
AUR102 (0)
EOC237 (0)
GTAEXS617 (0)
LY3405105 (0)
TGN-1062 (0)
TY-2699a (0)
XNW9015 (0)
SY-1365 (0)
CYC202 (0)
YPN-005 (7)
SY‑079 (4)
SY-5609 (3)
CT7001 (3)
TG02 (2)
BTX-A51 (1)
KRLS-017 (1)
AUR102 (0)
EOC237 (0)
GTAEXS617 (0)
LY3405105 (0)
TGN-1062 (0)
TY-2699a (0)
XNW9015 (0)
SY-1365 (0)
CYC202 (0)
›
Associations
(1)
News
Trials
Filter by
Latest
over1year
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=130, Recruiting, Qurient Co., Ltd. | N=70 --> 130
over 1 year ago
Enrollment change • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Keytruda (pembrolizumab) • Q901
over1year
Evaluation of the potential combination regimens for q901, a clinical stage selective cdk7 inhibitor, as a DNA damage repair inhibitor (AACR 2023)
The non-clinical data demonstrate that Q901 not only has a potential as a single agent,but can also be used in combination with other therapeutic strategies to develop next-generation cancer therapeutics to potentially address unmet medical needs.
over 1 year ago
Clinical • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
ER (Estrogen receptor) • BRCA (Breast cancer early onset)
|
ER positive • HR positive • BRCA wild-type
|
Q901
2years
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=70, Recruiting, Qurient Co., Ltd. | Not yet recruiting --> Recruiting
2 years ago
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Q901
over2years
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=70, Not yet recruiting, Qurient Co., Ltd.
over 2 years ago
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Q901
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login